Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGN-193408 SR
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic, Intraocular, Intracameral
01
Overview
AGN-193408 SR is a small molecule drug in development as a sustained-release intracameral (intraocular) implant for the treatment of open-angle glaucoma and ocular hypertension. It acts as an agonist of the prostaglandin F2 alpha receptor (PGF2α), lowering intraocular pressure by increasing aqueous humor outflow. The formulation is designed to provide prolonged drug delivery directly within the eye, potentially reducing dosing frequency compared to topical therapies. The developer and manufacturer is AbbVie (previously Allergan). As of early 2025, it is in Phase II clinical trials for both open-angle glaucoma and ocular hypertension[2][3][6][7].
- Other names
- AGN-193408 SRAGN193408 SRAGN 193408 SRAGN 193408 sustained-releaseAGN193408 sustained-releaseAGN-193408 sustained-release
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on AGN-193408 SR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGN-193408 SR.